Konica Minolta, a global digital technology company, completed acquisitionAmbry Genetics, a privately held healthcare company, for $1bn. Upon closure, $800m will be paid, and there will be an additional payment of up to $200m based on certain financial metrics over the next two years. Ambry’s genetic testing capabilities complement Konica Minolta’s advanced imaging technology to create the most comprehensive range of healthcare diagnostics for use by pharmaceutical companies, healthcare providers, payers, and consumers. “This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine. The future of medicine is patient-focused. Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual’s genetic and biochemical makeup, as well as the capabilities to translate that knowledge into information the medical community can use to discover, prevent, and cost-effectively treat diseases. This will not only serve as the future foundation for our healthcare business but will pave the way for a fundamental shift in the way medicine is practiced globally.” Shoei Yamana, Konica Minolta President and CEO.